knowledge -WSS

knowledge

author：comprehensive 2025-09-30 16:24:11 - browse：9

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Hottest summer in 2,000 years puts focus on extreme heat, health

focus

WSS

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

WHO recommends second malaria vaccine

Oak Street deal isn't the answer to health care's woes

Lilly’s weekly insulin works as well as daily products, new studies show

The White House hikes tariffs on plastic syringes made in China

Wikipedia

knowledge

focus

Medical records are filled with copy

The White House hikes tariffs on plastic syringes made in China

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

WHO recommends second malaria vaccine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

STAT reporters are Pulitzer Prize finalists for investigative reporting

Novavax promises a turnaround & Lilly roils the obesity market

As H5N1 spreads in cows, experts warn against drinking raw milk

Hepatitis C has a cure — but many Americans still lack access to it

Obesity drug from Roche shows promise in early study

leisure time

HHS suspends federal funding for EcoHealth Alliance

What a koala virus tells us about the human genome

Supreme Court to hear if Covid misinformation is protected speech

Medicare innovation center doesn’t save money, experts say

6 solutions to address cancer drug shortages and others

European officials brace for rough respiratory virus season

explore

focus

hotspot

focus